Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia

Oncology

Volumn 25, Issue 10, 2011, Pages

  George, James N ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLOOD SMEAR; BLOOD VESSEL OCCLUSION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; COOMBS TEST; EARLY DIAGNOSIS; EMBOLISM; ENZYME ACTIVITY; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MALIGNANCY ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA; MALIGNANT HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; PATHOGENESIS; PHYSICAL EXAMINATION; PREECLAMPSIA; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 80053633983     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Community Oncology. 2005;2:339-43.
2. Brain MC, Dacie JV, Hourihane OB. Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962;8:358-74.
3. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpura, and other thrombotic microangiopathies and coagulopathies. In: Jennett JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstalls Pathology of the Kidney, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 699-762.
4. George JN. How I treat patients with thrombotic thrombocytopenic purpura2010. Blood. 2010;116:4060-9.
5. Antman KH, Skarin AT, Mayer RJ, et al. Microangiopathic hemolytic anemia and cancer: a review. Medicine. 1979;58:377-84.
6. Francis KK, Kalyanam N, Terrell DR, et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 cases and a systematic review of the literature. The Oncologist. 2007;12:11-9.
7. Kremer Hovinga JA, Vesely SK, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500-11.
8. Benjamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009;48:1129-37.
9. Oberic L, Buffet M, Schwarzinger M, et al. Cancer awareness in atypical thrombotic microangiopathies. The Oncologist. 2009;14:769-79.
10. Elliott MA, Letendre L, Gastineau DA, et al. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010;85:43-50.
11. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011 June 14. [Epub ahead of print]
12. Egan JA, Bandarenko N, Hay SN, et al. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenic purpura. J Clin Apher. 2004;19:125-9.
13. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apher. 2001;16:202-9.
14. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781-9.
15. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664-70.
16. Izzedine H, Isnard-Bagnis C, Launey-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21:3038-45.
17. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8:634-41.
18. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008;87:495-6.
19. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5-8.
20. Nguyen L, Terrell DR, Duvall D, et al. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005-2008. Transfusion. 2009;49:392-4.
21. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apher. 2007;22:270-6.
22. Lu Q, Nedelcu E, Ziman A, et al. Standardized protocol to identify high-risk patients undergoing therapeutic apheresis procedures. J Clin Apher. 2008;23:111-15.
23. McCaleb E, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher. 2009;24:209-14.